Austin, Texas, June 5, 2014 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), a clinical stage, specialty biopharmaceutical company developing novel, non-aqueous formulations of injectable drugs, announced today the dosing of the first patient in a Phase 2 clinical study of the company’s stable, soluble glucagon in patients with type 1 diabetes under a new US Investigational New Drug (IND) application. Xeris’ G-Pen Mini™ (glucagon injection), a room-temperature stable glucagon product, is intended to be an effective and convenient treatment for mild-to-moderate hypoglycemia or low blood sugar.
Help employers find you! Check out all the jobs and post your resume.
